Su dhl 10

All DLBCL samples and clinicopathological data were obtained from the Sun Yat-sen University Cancer Center between 2006 and 2013. All patients or guardians provided written consent for the use of their data. The procedures of this study were approved by the Ethics Committee of Sun Yat-sen University Cancer Center. The wild-type TP53 human DLBCL cell lines OCI-Ly3 and OCI-Ly10 and mutated-type TP53 human DLBCL cells SU-DHL-6 and SU-DHL-10 were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). OCI-Ly3, OCI-Ly10, SU-DHL-6, and SU-DHL-10 cell lines were cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific, USA) containing 10% fetal bovine serum (FBS, HyClone, USA) and 1% penicillin-streptomycin solution (Gibco, 15140-122, Life Technologies, USA). All cells were cultured at 37 °C in a humidified atmosphere containing 5% CO₂. Peripheral blood mononuclear cells (PBMCs) and normal tonsil tissues were used as a control in this study.

The human DLBCL cell lines OCI‐LY3, OCI‐LY7, U2940, and WILL1 were purchased from Nanjing Kaiji Biotech (Nanjing, China). The human DLBCL cell lines SUDHL‐4 and SUDHL‐10 were purchased from FuHeng Cell Center (Shanghai, China). The human DLBCL cell lines SUDHL‐6, SUDHL‐8, and DB were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. Human DLBCL cell lines CTB1, KIS1, HBL‐1, MEDB1, BJAB, RI‐1, U2932, and FARAGE were purchased from Nanjing Daona Biological Technology Co., Ltd. (Nanjing, China). U2932, HBL‐1, FARAGE, CTB‐1, KIS1, BJAB, RI‐1, SU‐DHL‐4, SU‐DHL‐10, U2940, SU‐DHL‐6, and DB cells were grown in RPMI‐1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS), L‐glutamine, and penicillin/streptomycin. The WILL1 and SU‐DHL‐8 cell lines were grown in RPMI‐1640 medium supplemented with 20% FBS, L‐glutamine, and penicillin/streptomycin, and the OCI‐LY3, OCI‐LY7, and MEDB1 cell lines were maintained in IMDM (Gibco) complete medium.